Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 256Breast Neoplasms 173Neoplasms 169Colorectal Neoplasms 155Neoplasm Metastasis 126Melanoma 120Recurrence 118Prostatic Neoplasms 118Leukemia, Myeloid, Acute 117Pancreatic Neoplasms 115Ovarian Neoplasms 112Multiple Myeloma 104Lung Neoplasms 95Stomach Neoplasms 92Squamous Cell Carcinoma of Head and Neck 86Triple Negative Breast Neoplasms 85Glioblastoma 81Lymphoma 77Lymphoma, Non-Hodgkin 75Lymphoma, Large B-Cell, Diffuse 65Precursor Cell Lymphoblastic Leukemia-Lymphoma 64Carcinoma, Renal Cell 64Advanced Solid Tumor 59Endometrial Neoplasms 58Carcinoma, Hepatocellular 58Small Cell Lung Carcinoma 55Uterine Cervical Neoplasms 53Sarcoma 53Myelodysplastic Syndromes 51Leukemia 50

Interventions

BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Rhabdomyosarcoma, Alveolar × 1 year × Clear all
NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
31 enrolled 14 charts
LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡